Angle PLC Announces New Commercial Agreement with Large Pharma - Seite 2

1. Prostate cancer is the second most common cancer in men with 1.5 million new cases diagnosed globally each year and 5 million men living with prostate cancer (5-year prevalence). The androgen receptor plays a pivotal role in prostate cancer tumour growth and progression with anti-androgen therapy frequently given as first-line treatment. However, response is variable, and 20-30% of patients go on to develop resistance, resulting in disease progression and the development of metastatic castration resistant prostate cancer (mCRPC), which is currently incurable.

For further information:

ANGLE plc	[phone]
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Berenberg (NOMAD and Corporate Broker) Toby Flaux, Ciaran Walsh, Milo Bonser	[phone]
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US)	[phone] [phone]

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014). Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.

For Research Use Only. Not for use in diagnostic procedures.

For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/

Notes for editors

About ANGLE plc

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.